This material is best reviewed by Surgical Pathologists, Dermatopathologists, and Soft Tissue Pathology Fellows. The discussion centers on the diagnostic nuances of a rare mesenchymal neoplasm, emphasizing the importance of distinguishing it from reactive hemorrhagic processes and other translocation-associated sarcomas through morphology, immunohistochemistry (IHC), and molecular integration.
Abstract:
This clinical case study details the diagnosis of Angiomatoid Fibrous Histiocytoma (AFH) in a 67-year-old female—an unusually advanced age for this typically pediatric or young adult tumor. The lesion presented as a 2.5 cm circumscribed mass in the forefoot. Morphologically, the tumor exhibited classic features including a thick fibrous pseudo-capsule, peripheral lymphoplasmacytic cuffing, and blood-filled cystic spaces. However, the diagnosis was complicated by an abundance of hemosiderin and hematoidin, mimics of an old hematoma. Diagnosis was confirmed via an IHC profile of Desmin(+) and ALK-1(+) and molecular detection of an EWSR1::ATF1 gene fusion. The case underscores AFH’s status as a tumor of intermediate malignant potential and highlights the potential for pleomorphism despite its translocation-associated nature.
Case Analysis and Summary: Angiomatoid Fibrous Histiocytoma (AFH)
0:00 – Clinical Presentation: The patient is a 67-year-old female with a 2.5 cm, well-circumscribed mass located between the first and second metatarsal heads of the foot. Podiatry performed a complete excision following MRI.
0:38 – Low-Power Morphology: The lesion is well-circumscribed and characterized by a prominent fibrous capsule and extensive internal pigment.
1:53 – Cytological Challenges: Dense hemosiderin and reactive changes often obscure the underlying tumor cytology, making it difficult to differentiate tumor nuclei from reactive macrophages at lower magnifications.
2:41 – Hematoidin Identification: The presence of bright yellow, crystalline pigment—hematoidin—is noted. Unlike hemosiderin, hematoidin forms in low-oxygen environments (such as deep soft tissue pockets or seroma cavities) during the breakdown of hemoglobin to bilirubin.
3:45 – Immunohistochemical Profile: The cellular areas demonstrate positivity for Desmin and ALK-1 (clone D5F3), with focal, rare expression of EMA.
4:44 – Defining Diagnostic Features: AFH typically presents with sheets of histiocytoid/epithelioid cells, blood-filled cystic spaces, a peripheral pseudo-capsule, and a prominent cuff of lymphocytes and plasma cells.
5:45 – Diagnostic Pitfalls: The abundance of blood and pigment frequently leads to the misdiagnosis of a reactive process or an old hematoma. This case is noted for having an exceptional amount of hemosiderin compared to typical AFH presentations.
6:35 – Age Demographics: While AFH is primarily a tumor of childhood and young adulthood (20s–30s), this case highlights that it can occur in geriatric patients (age 67).
6:47 – Biological Behavior: Formerly classified as "angiomatoid malignant fibrous histiocytoma," it is now recognized as having intermediate malignant potential. It is prone to local recurrence and regional lymph node metastasis, but distant metastasis and fatality are extremely rare.
7:42 – Molecular Genetics: AFH is associated with three main translocations: EWSR1::CREB1 (most common), EWSR1::ATF1, and FUS::ATF1.
8:09 – Molecular Overlap: The EWSR1::ATF1 fusion is also pathognomonic for Clear Cell Sarcoma, though the two tumors are morphologically and clinically distinct.
8:53 – Morphological Pearls: While many translocation-associated tumors are characterized by monotonous, uniform nuclei, AFH is a notable exception and frequently exhibits scattered pleomorphism.
9:48 – Nomenclature Clarification: Despite the name, AFH is biologically unrelated to benign "fibrous histiocytoma" (dermatofibroma).
10:14 – Clinical Management: Due to the risk of recurrence and regional metastasis, wide local excision with negative margins is the standard of care.